A prospective, interventional clinical study to evaluate the safety and efficacy of Liv.52 DS in the management of non-alcoholic fatty liver disease

• Authors: Gontar Siregar , Rangesh Paramesh , Rajesh Kumawat , Palaniyamma D , Srikrishna HA

Abstracts

EN

Introduction. Non-alcoholic fatty liver disease (NAFLD) is excessive fat build-up in the liver due to causes other than alcohol use. Aim. To evaluate the clinical efficacy and safety of Liv.52 DS tablets in the management of NAFLD. Material and methods. Prospective, interventional clinical study conducted on 60 patients of both sex, aged between 18-65 years, confirmed with NAFLD from clinical examination, laboratory test, ultrasound findings and those willing to give informed consent. All patients received Liv.52 DS at a dose of 2 tablets twice daily for 2 months. All patients were evaluated at baseline, end of 1st month, and end of 2nd month for liver function tests, hepatomegaly by ultrasound, NAFLD Fibrosis Score, lipid profile, hematology and biochemical investigations. Results. Study data was analyzed with GraphPad Prism Software Version 6.07. Data of those patients who completed the study was considered for analysis. Significant improvement in hepatomegaly, liver enzymes was observed. NAFLD fibrosis score revealed no progression of liver fibrosis due to NAFLD during the study period. No abnormal lab values were recorded and there were no adverse events reported during the study. Conclusion. Study concludes that Liv.52 DS is safe and beneficial in individuals suffering from NAFLD.

Keywords

EN

ALT/AST; fatty liver; fibrosis; non-alcoholic fatty liver disease

• Publisher: Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
• Journal: European Journal of Clinical and Experimental Medicine
• Year: 2021
• Issue: 2
• Pages: 129-136

Dates

published

2021

Contributors

author

Gontar Siregar

• Division of Gastroenterology-Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Sumatera Utara, Medan, Indonesia

author

Rangesh Paramesh

• The Himalaya Drug Company, Makali, Bengaluru, India

author

Rajesh Kumawat

• The Himalaya Drug Company, Makali, Bengaluru, India

author

Palaniyamma D

• The Himalaya Drug Company, Makali, Bengaluru, India

author

Srikrishna HA

• The Himalaya Drug Company, Makali, Bengaluru, India

Identifiers

DOI

10.15584/ejcem.2021.2.3

Biblioteka Nauki

2038171